Corrigendum to “The Pivotal Role of Cd69 in Autoimmunity” [J. Autoimmun. 111C (2020) 102453] (Journal of Autoimmunity (2020) 111, (S0896841120300688), (10.1016/J.Jaut.2020.102453)) Publisher Pubmed



Gorabi AM¹ ; Hajighasemi S² ; Kiaie N¹ ; Gheibi Hayat SM³ ; Jamialahmadi T^{4, 5} ; Johnston TP⁶ ; Sahebkar A^{7, 8, 9}
Source: Journal of Autoimmunity Published:2020

Abstract

The authors would like to inform the readers that errors were made in the original article (1): - References 14, 93, 68, 90, 67, 89, 75, 79, 91, 92, 94, and 95 are duplicate to references 2, 24, 33, 40, 59, 62, 64, 73, 82, 83, 84, and 86, respectively. - Figure 4 of this review article has been reproduced from (2) with permission. - Figure 2 of this review article and its legend have been reproduced with slight modifications from (3) with permission. The legend should read, “signaling created by CD69 and S1P1 leads to TH1/TH17 polarization. Binding of the S1P to S1P1 receptor enhances the activity of the mTOR/HIF-1α and JAK2/pSTAT3 pathways, which both eventually increase TH1/TH17 phenotype and inhibit Treg-cell differentiation. On the other hand, CD69 inhibits S1P1-induced signaling by upregulating the JAK3/pSTAT5 pathway, which counteracts STAT3-induced expression of IL-17 and promotes Treg development. Furthermore, the interaction of CD69 with Gal-1 could potentially modulate these CD69-mediated effects (3)”. Citation of the original article is already present in the published review (no. 25). We regret that permission to reproduce figures was obtained after submission. We also thank Professor Pilar Martin and Francisco Sanchez-Madrid for bringing these errors to our attention. References. 1. Gorabi AM, Hajighasemi S, Kiaie N, Gheibi Hayat SM, Jamialahmadi T, Johnston TP, Sahebkar A. The pivotal role of CD69 in autoimmunity. J Autoimmun. 2020 Jul; 111:102453. doi: 10.1016/j.jaut.2020.102453. 2. Gonzalez-Amaro R, Cortes JR, Sanchez-Madrid F, Martin P. Is CD69 an effective brake to control inflammatory diseases? Trends Mol Med. 2013 Oct; 19(10):625-32. doi: 10.1016/j.molmed.2013.07.006. 3. Cibrian D, Sanchez-Madrid F. CD69: from activation marker to metabolic gatekeeper. Eur J Immunol. 2017 Jun; 47(6):946–953. doi: 10.1002/eji.201646837. The authors wish to apologise for any inconvenience caused. © 2020 Elsevier Ltd